Search Result "Natalizumab treatment"
The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders
Journal: CNS & Neurological Disorders - Drug Targets
Volume: 17 Issue: 6 Year: 2018 Page: 464-472
Author(s): Rodica Balasa,Ciurba Bianca,Voidezan Septimiu,Simu Iunius,Hutanu Adina,Andone Sebastian,Romaniuc Andreea,Motataianu Anca,Maier Smaranda
Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Journal: Current Molecular Medicine
Volume: 15 Issue: 10 Year: 2015 Page: 990-993
Author(s): M. Galuppo,E. Mazzon,S. Giacoppo,O. Bereshchenko,S. Bruscoli,C. Riccardi,P. Bramanti
Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Journal: Current Medicinal Chemistry
Volume: 16 Issue: 3 Year: 2009 Page: 4858-4868
Author(s): F. Di Pauli, T. Berger, M. Reindl
Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action
Journal: CNS & Neurological Disorders - Drug Targets
Volume: 16 Issue: 9 Year: 2017 Page: 1018-1026
Author(s): Rodica Ioana Balasa,Mihaela Simu,Septimiu Voidazan,Laura Iulia Barcutean,Zoltan Bajko,Adina Hutanu,Iunius Simu,Smaranda Maier
A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Journal: Current Drug Metabolism
Volume: 19 Issue: 14 Year: 2018 Page: 1213-1223
Author(s): Hao Li,Fang-Hong Shi,Shi-Ying Huang,Shun-Guo Zhang,Min-Ling Chen
Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies
Journal: Current Drug Safety
Volume: 10 Issue: 3 Year: 2015 Page: 217-220
Author(s): Yara Dadalti Fragoso
Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Journal: Current Pharmaceutical Design
Volume: 22 Issue: 3 Year: 2016 Page: 4876-4880
Author(s): Begona M. Escribano, Macarena Aguilar-Luque, Carmen Bahamonde, Cristina Conde, Rafael Lillo, Fernando Sanchez-Lopez, Ana I. Giraldo, Antonio H. Cruz, Evelio Luque, Felix Gascon, Eduardo Aguera, Isaac Tunez
The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Journal: Inflammation & Allergy - Drug Targets (Discontinued)
Volume: 13 Issue: 2 Year: 2014 Page: 121-127
Author(s): Eric Toussirot,Matthieu Bereau
Real-World Data Regarding Long-Term Administration of NatalizumabDerived from a Neurology Department along with Literature Review
Journal: CNS & Neurological Disorders - Drug Targets
Volume: 21 Issue: 4 Year: 2022 Page: 326-334
Author(s): Eugenia Irene Davidescu,Irina Odajiu,Constantin-DragoÈ Sandu,Amalia Ghergu,Dimela Luca,Dafin Fior MureÈanu,Bogdan Ovidiu Popescu
Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 29 Year: 2012 Page: 4550-4555
Author(s): Nicolas von Ahsen,Andrew Chan